A practical framework categorizes TKIs into three classes to guide adjuvant use. Class 1 (e.g., osimertinib, alectinib) has high efficacy and low toxicity, making extrapolation easy. Class 2 (e.g., BRAF/MET inhibitors) has moderate efficacy and higher toxicity, requiring trials. Class 3 (e.g., KRAS inhibitors) has lower activity and needs trials.

Despite both Zongertinib and Sevabirtinib showing high efficacy in HER2-mutant NSCLC, Zongertinib's selective nature results in a much better safety profile. Sevabirtinib's dual EGFR/HER2 inhibition leads to significant GI and skin toxicities, making tolerability, not just efficacy, the key factor for clinical preference.

While the new CML drug Asciminib demonstrates better efficacy, its most significant advantage is superior tolerability. Clinical trial data shows it causes significantly fewer treatment discontinuations due to adverse events compared to both Imatinib and second-generation TKIs, improving patient adherence and quality of life.

While newer ROS1 inhibitors have overlapping efficacy, their side effect profiles differ. Repotrectinib is more associated with neurological issues, while taletrectinib can cause more gastrointestinal distress. This allows clinicians to sequentially switch patients between these agents to find a tolerable long-term option.

Even if randomized trials show zongertinib's efficacy is merely comparable to chemoimmunotherapy, its significantly milder safety profile—especially its lack of cardiac toxicity and manageable side effects—is expected to make it the preferred first-line choice. Patient quality of life and tolerability are becoming decisive factors in treatment selection.

The ALK inhibitor lorlatinib frequently causes neuropsychiatric side effects like mood and cognitive changes, often requiring medication. Patients are typically unaware of these shifts in their behavior. It is therefore crucial for clinicians to explicitly educate family members on what to watch for and to report any changes.

The development of PARP-1 selective inhibitors like seriparib signals a shift in drug innovation. Instead of only chasing higher efficacy, these new agents aim for a more favorable toxicity profile (less GI toxicity, fewer dose discontinuations) to improve patient quality of life and treatment adherence.

Despite a more challenging neurocognitive side effect profile, lorlatinib's median progression-free survival (PFS) of over seven years has shifted expert practice. This remarkable efficacy now positions it as the preferred first-line agent over better-tolerated second-generation TKIs for ALK-positive NSCLC.

After a first-in-class drug proves a therapeutic approach works, the competitive landscape shifts. Second-generation drugs cannot just offer marginal efficacy gains. Instead, they must provide a significantly better quality of life and tolerability profile, as patients will be living with the side effects for longer periods of extended survival.